Jordan E Roberts1, Lauren A Henderson. 1. Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: To review diagnosis, clinical characteristics and treatment of multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RECENT FINDINGS: MIS-C emerged in spring 2020 as a hyperinflammatory syndrome following SARS-CoV-2 exposure in children. Despite growing awareness of MIS-C, diagnosis remains challenging due to the range of phenotypes and severity. Fever accompanied by shock, cardiac dysfunction, gastrointestinal symptoms, or mucocutaneous signs suggestive of Kawasaki disease, especially in the presence of known or suspected coronavirus disease 2019 exposure, should trigger consideration of MIS-C. However, clinical presentations are highly varied and may overlap with other infectious diseases. Clinicians must maintain a high index of suspicion for MIS-C and be aware that patients may develop coronary artery aneurysms and myocarditis even with few or no Kawasaki disease symptoms. More precise diagnostic criteria and specific biomarkers are needed to aid diagnosis. Intravenous immunoglobulin (IVIG) is first-line therapy, and steroids should be considered as initial adjunctive treatment for patients with severe manifestations or other risk factors. Prompt treatment is essential, as patients may worsen acutely, though overall prognosis is reassuring. SUMMARY: MIS-C associated with SARS-CoV-2 has varied clinical manifestations. Clinicians must be aware of the common presentation and potential for decompensation and cardiac sequalae to guide appropriate evaluation and treatment.
PURPOSE OF REVIEW: To review diagnosis, clinical characteristics and treatment of multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RECENT FINDINGS: MIS-C emerged in spring 2020 as a hyperinflammatory syndrome following SARS-CoV-2 exposure in children. Despite growing awareness of MIS-C, diagnosis remains challenging due to the range of phenotypes and severity. Fever accompanied by shock, cardiac dysfunction, gastrointestinal symptoms, or mucocutaneous signs suggestive of Kawasaki disease, especially in the presence of known or suspected coronavirus disease 2019 exposure, should trigger consideration of MIS-C. However, clinical presentations are highly varied and may overlap with other infectious diseases. Clinicians must maintain a high index of suspicion for MIS-C and be aware that patients may develop coronary artery aneurysms and myocarditis even with few or no Kawasaki disease symptoms. More precise diagnostic criteria and specific biomarkers are needed to aid diagnosis. Intravenous immunoglobulin (IVIG) is first-line therapy, and steroids should be considered as initial adjunctive treatment for patients with severe manifestations or other risk factors. Prompt treatment is essential, as patients may worsen acutely, though overall prognosis is reassuring. SUMMARY: MIS-C associated with SARS-CoV-2 has varied clinical manifestations. Clinicians must be aware of the common presentation and potential for decompensation and cardiac sequalae to guide appropriate evaluation and treatment.
Authors: Pui Y Lee; Megan Day-Lewis; Lauren A Henderson; Kevin G Friedman; Jeffrey Lo; Jordan E Roberts; Mindy S Lo; Craig D Platt; Janet Chou; Kacie J Hoyt; Annette L Baker; Tina M Banzon; Margaret H Chang; Ezra Cohen; Sarah D de Ferranti; Audrey Dionne; Saddiq Habiballah; Olha Halyabar; Jonathan S Hausmann; Melissa M Hazen; Erin Janssen; Esra Meidan; Ryan W Nelson; Alan A Nguyen; Robert P Sundel; Fatma Dedeoglu; Peter A Nigrovic; Jane W Newburger; Mary Beth F Son Journal: J Clin Invest Date: 2020-11-02 Impact factor: 14.808
Authors: Leora R Feldstein; Erica B Rose; Steven M Horwitz; Jennifer P Collins; Margaret M Newhams; Mary Beth F Son; Jane W Newburger; Lawrence C Kleinman; Sabrina M Heidemann; Amarilis A Martin; Aalok R Singh; Simon Li; Keiko M Tarquinio; Preeti Jaggi; Matthew E Oster; Sheemon P Zackai; Jennifer Gillen; Adam J Ratner; Rowan F Walsh; Julie C Fitzgerald; Michael A Keenaghan; Hussam Alharash; Sule Doymaz; Katharine N Clouser; John S Giuliano; Anjali Gupta; Robert M Parker; Aline B Maddux; Vinod Havalad; Stacy Ramsingh; Hulya Bukulmez; Tamara T Bradford; Lincoln S Smith; Mark W Tenforde; Christopher L Carroll; Becky J Riggs; Shira J Gertz; Ariel Daube; Amanda Lansell; Alvaro Coronado Munoz; Charlotte V Hobbs; Kimberly L Marohn; Natasha B Halasa; Manish M Patel; Adrienne G Randolph Journal: N Engl J Med Date: 2020-06-29 Impact factor: 91.245
Authors: Caroline Diorio; Sarah E Henrickson; Laura A Vella; Kevin O McNerney; Julie Chase; Chakkapong Burudpakdee; Jessica H Lee; Cristina Jasen; Fran Balamuth; David M Barrett; Brenda L Banwell; Kathrin M Bernt; Allison M Blatz; Kathleen Chiotos; Brian T Fisher; Julie C Fitzgerald; Jeffrey S Gerber; Kandace Gollomp; Christopher Gray; Stephan A Grupp; Rebecca M Harris; Todd J Kilbaugh; Audrey R Odom John; Michele Lambert; Emily J Liebling; Michele E Paessler; Whitney Petrosa; Charles Phillips; Anne F Reilly; Neil D Romberg; Alix Seif; Deborah A Sesok-Pizzini; Kathleen E Sullivan; Julie Vardaro; Edward M Behrens; David T Teachey; Hamid Bassiri Journal: J Clin Invest Date: 2020-11-02 Impact factor: 14.808
Authors: Brian Jonat; Mark Gorelik; Alexis Boneparth; Andrew S Geneslaw; Philip Zachariah; Amee Shah; Larisa Broglie; Juan Duran; Kimberly D Morel; Maria Zorrilla; Leanne Svoboda; Candace Johnson; Jennifer Cheng; Maria C Garzon; Wendy G Silver; Kara Gross Margolis; Cindy Neunert; Irene Lytrivi; Joshua Milner; Steven G Kernie; Eva W Cheung Journal: Pediatr Crit Care Med Date: 2021-03-01 Impact factor: 3.971